MoBeta awarded radioactive stent patent

MoBeta, Inc. a pre-IPO R&D start-up company, today announced that U.S. Patent Number 6,264,595 for radioactive transition metal stents was assigned to MoBeta, Inc. The patent is intended to address the therapeutic and diagnostic applications of implantable medical devices like stents in which the placement of transient radiation is deemed beneficial.

The MoBeta, Inc. patent claims a radioactive transition metal stent with a chemically bound radioactive surface and a methodology for forming a radioactive transition metal metaphoshate and phosphide stent surface. Radioactive phosphorus atoms chemically bound in this way ensure high activity and remarkable stability. Transition metal stents include those made of stainless-steel, the shape memory alloy nitinol, and tantalum, among others.

Michelangelo Delfino, Ph.D., MoBeta, Inc.'s vice president and co-inventor stated, "Ours is a chemically bonded radioactive surface in which the pure beta-radiation emitter phosphorus-32 is conformally distributed on the stent or alternatively confined to the distal ends, for example, to produce a more selective and localized source of healing radiation." Beta radiation has shown desirable effects in the treatment of restenosis, the regrowth of scar tissue associated with balloon angioplasty failure. Phosphorus-32 with it's 14.3 day half-life is perhaps the most popular and least-expensive source of beta-radiation per dose being experimented with today. Delfino added, "We believe that beta-radioactive medical devices will improve the quality of our lives and see MoBeta, Inc.'s patents contributing."

About MoBeta, Inc.

MoBeta, Inc. is a pre-IPO R&D start-up company specializing in the creation of novel medical technology located in Los Altos, California. Incorporated in January 1999, it maintains a website at www.mobetainc.com .

Source: MoBeta, Inc.